| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Telaprevir |
| Brand | Incivo® |
| Indication | As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
| Assessment Process | |
| Rapid review commissioned | 28/10/2011 |
| Rapid review completed | 02/11/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 08/11/2011 |
| NCPE assessment completed | 19/01/2012 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider telaprevir (Incivo®) a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.